Search bioRxiv⌕ Search

Biology subjects

Brosnan-Cashman, J.

Publications and source records attributed to Brosnan-Cashman, J..

2 recordsLinked to original sources

Spatial mapping of immunosuppressive cancer-associated fibroblast gene signatures in H&E-stained images using additive multiple instance learning

The relative abundance of cancer-associated fibroblast (CAF) subtypes influences a tumors response to treatment, especially immunotherapy. However, the extent to which the underlying tumor composition associates with CAF subtype-specific gene expression is unclear. Here, we describe an interpretable machine learning (ML) approach, additive multiple instance learning (aMIL), to predict bulk gene expression signatures from H&E-stained whole slide images (WSI), focusing on an immunosuppressive LRRC15+ CAF-enriched TGF{beta}-CAF signature. aMIL models accurately predicted TGF{beta}-CAF across various cancer types. Tissue regions contributing most highly to slide-level predictions of TGF{beta}-CAF were evaluated by ML models characterizing spatial distributions of diverse cell and tissue types, stromal subtypes, and nuclear morphology. In breast cancer, regions contributing most to TGF{beta}-CAF-high predictions ("excitatory") were localized to cancer stroma with high fibroblast density and mature collagen fibers. Regions contributing most to TGF{beta}-CAF-low predictions ("inhibitory") were localized to cancer epithelium and densely inflamed stroma. Fibroblast and lymphocyte nuclear morphology also differed between excitatory and inhibitory regions. Thus, aMIL enables a data-driven link between tissue phenotype and transcription, offering biological interpretability beyond typical black-box models.

cancer biology↗

IDH1R132H acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage response

One sentence summaryMutant IDH1 acts as a tumor suppressor when co-expressed together with TP53 and ATRX inactivating mutations in glioma, inducing genomic stability, DNA repair and resistance to genotoxic therapies.\n\nAbstractGlioma patients whose tumors carry a mutation in the Isocitrate Dehydrogenase 1 (IDH1R132H) gene are younger at the time of diagnosis and survive longer. The molecular glioma subtype which we modelled, harbors IDH1R132H, tumor protein 53 (TP53) and alpha-thalassemia/mental retardation syndrome X-linked (ATRX) loss. The impact of IDH1R132H on genomic stability, DNA damage response (DDR) and DNA repair in this molecular glioma subtype is unknown. We discovered that IDH1R132H expression in the genetic context of ATRX and TP53 inactivation: (i) increases median survival (MS), (ii) enhances DDR activity via epigenetic upregulation of Ataxia-telangiectasia mutated (ATM) signaling, and (iii) elicits tumor radioresistance. Pharmacological inhibition of ATM or checkpoint kinase 1 and 2 (CHK1/2), two essential kinases in the DDR pathways, restored tumors radiosensitivity. Translation of these findings for mlDH1 glioma patients could significantly improve the therapeutic efficacy of radiotherapy, and thus have a major impact on patient survival.

cancer biology↗